The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mitsuo Satoh, head of Kyowa Hakko Kirin’s R&D division, said: “As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Artificial intelligence and machine learning company InveniAI has joined with Kyowa Hakko Kirin to harness the power of technology for drug discovery. In this case Kyowa Hakko Kirin will use ...

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin ...

As work progresses on an up-and-coming biologics plant in North Carolina, specialty pharma company Kyowa Kirin has completed another in its home country of Japan. Kyowa Kirin has finished the ...

We appreciate the support and cooperation we enjoy with our partner Kyowa Kirin, and we look forward with confidence to the continued progress of this program and our collaboration.” Ziftomenib ...

Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation - SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq ...

Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML.